Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has been given a $4.00 target price by HC Wainwright in a note issued to investors on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 86.92% from the company’s current price.

A number of other equities research analysts have also commented on the company. Piper Jaffray Companies restated a “buy” rating and set a $4.00 price target on shares of Idera Pharmaceuticals in a research report on Tuesday, September 12th. Zacks Investment Research upgraded Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. ValuEngine lowered Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, BidaskClub lowered Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. Idera Pharmaceuticals has an average rating of “Buy” and a consensus price target of $4.83.

Shares of Idera Pharmaceuticals (IDRA) opened at $2.14 on Thursday. Idera Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $2.87.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.02. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 60.80% and a negative net margin of 313.78%. equities research analysts predict that Idera Pharmaceuticals will post -0.43 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Idera Pharmaceuticals, Inc. (IDRA) Given a $4.00 Price Target by HC Wainwright Analysts” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/idera-pharmaceuticals-inc-idra-given-a-4-00-price-target-by-hc-wainwright-analysts/1710798.html.

In other news, Director Bros. Advisors Lp Baker acquired 8,000,000 shares of Idera Pharmaceuticals stock in a transaction on Thursday, October 26th. The shares were purchased at an average price of $1.50 per share, with a total value of $12,000,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 30.29% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its holdings in Idera Pharmaceuticals by 0.3% during the 2nd quarter. Rhumbline Advisers now owns 118,456 shares of the biotechnology company’s stock worth $204,000 after buying an additional 312 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Idera Pharmaceuticals by 0.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 343,761 shares of the biotechnology company’s stock worth $591,000 after buying an additional 2,368 shares in the last quarter. Wedbush Securities Inc. lifted its holdings in Idera Pharmaceuticals by 3.0% during the 2nd quarter. Wedbush Securities Inc. now owns 93,428 shares of the biotechnology company’s stock worth $161,000 after buying an additional 2,700 shares in the last quarter. American International Group Inc. lifted its holdings in Idera Pharmaceuticals by 8.2% during the 1st quarter. American International Group Inc. now owns 55,412 shares of the biotechnology company’s stock worth $137,000 after buying an additional 4,214 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Idera Pharmaceuticals by 5.8% during the 1st quarter. Wells Fargo & Company MN now owns 91,479 shares of the biotechnology company’s stock worth $226,000 after buying an additional 5,000 shares in the last quarter. 23.73% of the stock is currently owned by hedge funds and other institutional investors.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Analyst Recommendations for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.